Die medikamentöse Therapie des HCC mit Sorafenib – der Beginn einer neuen Ära in der Behandlung des HCC

Zusammenfassung

Seit 2007 steht mit Sorafenib erstmals eine wirksame Therapie für Patienten mit einem HCC zur Verfügung, die zu einer Verlängerung des mittleren Überlebens von fast 3 Monaten geführt hat. Trotzdem bleibt auch bei dieser Therapie das mittlere Gesamtüberleben für Patienten mit einem fortgeschrittenen HCC unter 1 Jahr. Basierend auf Untersuchungen zur molekularen Karzinogenese einerseits, und andererseits der Entwicklung von neuen molekularen Therapien in anderen Indikationen und Ergebnissen von Biomarkeruntersuchungen bei Patienten mit HCC unter Therapie, werden derzeit neue Therapiestrategien zur Behandlung des HCC im Rahmen von klinischen Studien evaluiert. Im Folgenden fassen wir die aktuellen Kenntnisse zur molekularen Therapie des HCC zusammen und zeigen Wege auf, wie neue Substanzen effektiv in der Indikation des HCC evaluiert werden können.

Abstract

Sorafenib increases overall survival in patients with advanced HCC by almost three months. However, despite these advances in the treatment of patients with HCC, average overall survival remains below one year. Based on our understanding of hepatocarcinogenesis, the development of new molecular targeting agents and results from biomarker studies in HCC, new therapeutic treatment options are currently being investigated. We summarize recent results on the molecular therapy for HCC and discuss how these can be efficiently tested in patients with HCC.

Schlüsselwörter

HCC - Chemotherapie - neue molekulare Therapie

Key words

HCC - Chemotherapy - Molecular targeted therapy

Literatur

• 1 Ferlay J, Autier P, Boniol M. et al . Estimates of the cancer incidence and mortality in Europe in 2006.  Ann Oncol. 2007;  18 581-592
• 2 Greten T F, Wedemeyer H, Manns M P. Prävention Virus-assoziierter Karzinomentstehung: Am Beispiel des hepatozellulären Karzinoms.  Deutsches Ärzteblatt. 2006;  103 A-1817
• 3 Jemal A, Siegel R, Ward E. et al . Cancer statistics, 2007.  CA Cancer J Clin. 2007;  57 43-66
• 4 Greten T F, Papendorf F, Bleck J S. et al . Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients.  Br J Cancer. 2005;  92 1862-1868
• 5 Greten T F, Blum H E, Manns M P. et al . Therapie des hepatozellulären Karzinoms.  Z Gastroenterol. 2006;  44 43-49
• 6 Escudier B, Eisen T, Stadler W M. et al . Sorafenib in advanced clear-cell renal-cell carcinoma.  N Engl J Med. 2007;  356 125-134
• 7 Strumberg D, Clark J W, Awada A. et al . Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.  Oncologist. 2007;  12 426-437
• 8 Llovet J M, Ricci S, Mazzaferro V. et al . Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med. 2008;  359 378-390
• 9 Pang R W, Poon R T. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.  Oncology. 2007;  72 (Suppl 1) 30-44
• 10 Zhu A X, Blaszkowsky L S, Ryan D P. et al . Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.  J Clin Oncol. 2006;  24 1898-1903
• 11 Thomas M B, Chadha R, Iwasaki M. et al . The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2007;  25 4567
• 12 Zhu A X, Sahani D V, Tomaso di E. et al . A phase II study of sunitinib in patients with advanced hepatocellular carcinoma.  J Clin Oncol. 2007;  25 4637
• 13 Koch I, Baron A, Roberts S. et al . Influence of Hepatic Dysfunction on Safety, Tolerability, and Pharmacokinetics (PK) of PTK787 /ZK 222 584 in Patients with Unresectable Hepatocellular Carcinoma.  J Clin Oncol. 2005;  23 4134
• 14 Drevs J, Siegert P, Medinger M. et al . Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.  J Clin Oncol. 2007;  25 3045-3054
• 15 Podar K, Tonon G, Sattler M. et al . The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.  Proc Natl Acad Sci USA. 2006;  103 19 478-19 483
• 16 Thomas M B, Chadha R, Glover K. et al . Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.  Cancer. 2007;  110 1059-1067
• 17 Semela D, Piguet A C, Kolev M. et al . Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.  J Hepatol. 2007;  46 840-848
• 18 Knight B, Tirnitz-Parker J E, Olynyk J K. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.  Gastroenterology. 2008;  135 979 e961
• 19 Eckel F, Delius von S, Mayr M. et al . Pharmacokinetic and clinical phase ii trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma.  Oncology. 2005;  69 363-371
• 20 Lin A Y, Fisher G A, So S. et al . Phase II study of imatinib in unresectable hepatocellular carcinoma.  Am J Clin Oncol. 2008;  31 84-88
• 21 Wang Z, Zhou J, Fan J. et al . Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.  Clin Cancer Res. 2008;  14 5124-5130
• 22 Pena C, Shan M, Wilhelm S. et al . Hepatocyte growth factor (HGF) is a prognostic biomarker for overall survival and a pharmacodynamic biomarker of sorafenib response in the SHARP III HCC trials.  Annals of Oncology. 2008;  19 (Suppl 8) viii153-viii165
• 23 Llovet J M, Di Bisceglie A M, Bruix J. et al . Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma.  J Natl Cancer Inst. 2008;  100 698-711
• 24 Kanai F, Yoshida H, Teratani T. et al . New feasibility study design with hepatocellular carcinoma: A phase I/II study of TSU-68, an oral angiogenesis inhibitor.  J Clin Oncol. 2006;  24 4145
• 25 Siegel A B, Cohen E I, Ocean A. et al . Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.  J Clin Oncol. 2008;  26 2992-2998
• 26 Malka D, Dromain C, Farace F. et al . Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring.  J Clin Oncol. 2007;  25 4570
• 27 Sun W, Haller D G, Mykulowycz K. et al . Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study.  J Clin Oncol. 2007;  25 4574
• 28 Hsu C, Yang T, Hsu C. et al . Modified-dose capecitabine+bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study.  J Clin Oncol. 2007;  25 15 190
• 29 Faivre S J, Raymond E, Douillard J. et al . Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC).  J Clin Oncol. 2007;  25 3546
• 30 Hoda D, Catherine C, Strosberg J. et al .Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium Orlando; 2008
• 31 Philip P A, Mahoney M R, Allmer C. et al . Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.  J Clin Oncol. 2005;  23 6657-6663
• 32 O’Dwyer P J, Giantonio B J, Levy D E. et al . Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E 1203.  J Clin Oncol. 2006;  24 4143
• 33 Ramanathan R K, Belani C P, Singh D A. et al . Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2 /Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial.  J Clin Oncol. 2006;  24 4010
• 34 Zhu A X, Stuart K, Blaszkowsky L S. et al . Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.  Cancer. 2007;  110 581-589
• 35 Grunwald V, Wilkens L, Gebel M. et al . A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results.  J Clin Oncol. 2007;  25 4598
• 36 Louafi S, Hebbar M, Rosmorduc O. et al . Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO.  J Clin Oncol. 2007;  25 4594
• 37 O’Neil B H, Bernard S A, Goldberg R M. et al . Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma.  J Clin Oncol. 2008;  26 4604
• 38 Greten T F, Korangy F, Manns M P. et al . Molecular therapy for the treatment of hepatocellular carcinoma.  Br J Cancer. 2008 [in press];